Methylphenidate and atomoxetine in attention deficit hyperactivity disorder
Phase 3
- Conditions
- Attention deficit hyperactivity disorder in adults.Attention-deficit hyperactivity disorder, unspecified type
- Registration Number
- IRCT20110802007202N15
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Attention Deficit Hyperactivity Disorder
Age between 19-50 years
Signing consent form
Exclusion Criteria
Patients with a history of any systemic disorder such as cardiovascular diseases
Patients with a history of bipolar disorder, major depressive disorder, psychosis, substance abuse, pervasive developmental disorder and intellectual disability
Using psychotropic drugs within one month prior to the initiation of the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Score of inattentive and hyperactive symptoms in Conners Adult ADHD Rating Scale - self report questionnaire. Timepoint: Before intervention and 2, 4, 6 and 8 weeks after the intervention. Method of measurement: Self report Conners Adult ADHD Rating Scale questionnaire.
- Secondary Outcome Measures
Name Time Method The score of Hamilton Depression questionnaire. Timepoint: Before intervention and 8 weeks after the intervention. Method of measurement: Hamilton depression questionnaire.;The score of Hamilton Anxiety questionnaire. Timepoint: Before intervention and 8 weeks after the intervention. Method of measurement: Hamilton Anxiety questionnaire.;The score of general assessment of functioning scale. Timepoint: Before intervention and 8 weeks after the intervention. Method of measurement: General assessment of functioning scale.